Sense Signs UK Distribution Agreement with Una Health for Point-of-Care PCR Quality Covid-19 Test

Partnership anticipates imminent UK launch of the first test from the instrument-free Veros™ platform

BOSTON & OXFORD, England & CAMBRIDGE, England–(BUSINESS WIRE)–Global molecular diagnostics innovator, Sense Biodetection (Sense), today announced that it has entered into a strategic agreement with Una Health (Una) for the UK distribution of the Veros Covid-19 Test, the first test on Sense’s Veros rapid, instrument-free, point-of-care molecular testing platform. The self-contained, single use Veros platform produces PCR lab quality results in 15 minutes without a reader or external power. Una is a leading specialty medical distributor focused on improving outcomes at the point-of-care and is well-known for its ability to cultivate new markets with innovative technology. For Sense, the agreement with Una is the first in a series of expected announcements in anticipation of regulatory approvals to commercialize its Veros platform in the UK and Europe.

“Una is an ideal commercial partner because of its exceptional experience in launching new products and creating opportunities for improved patient care,” commented Ryan Roberts, Chief Commercial Officer at Sense. “Una’s strong relationships with customers in the point-of-care segment will be well served by the benefits that our rapid Veros Covid test can bring to the healthcare delivery process, providing the confidence of lab quality results wherever they are needed. We look forward to working with Una as we introduce the first Veros branded products to UK customers.”

“Being able to offer our customers an instrument free, PCR-quality result in minutes and at the point of care is exactly the kind of product that reflects our ethos of delivering product offerings that improve operational, clinical and economic outcomes in the healthcare system,” said Fiona Jacobs, Managing Director of Una Health. “As the Corona virus continues to significantly impact all aspects of society, the Veros Covid-19 Test is a powerful tool to help us return to our normal lives.”

Veros has the potential to be the first and only instrument-free, single-use, rapid, point-of-care molecular diagnostic testing platform that produces lab-quality results within 15 minutes. Unconstrained by an instrument or reader, the Veros platform can help to improve access to rapid, highly accurate, point of care testing for many more people. In its first application, Veros can help improve speed to treatment and reduce the spread of COVID-19 with faster, more precise diagnoses. Using a proprietary, rapid molecular amplification technology, Veros aims to deliver instrument-free, PCR-quality laboratory results directly to users within minutes.

###

About Sense Biodetection

Sense Biodetection is a global molecular diagnostics company focused on empowering patients and transforming healthcare access and affordability by bringing lab-quality results through easy-to-use, rapid, disposable molecular tests without the constraints of an instrument. The company’s Veros product platform will enable widespread testing to enhance patient access, improve patient health and lower systemic healthcare costs. Backed by respected investors, such as Koch Disruptive Technologies, Cambridge Innovation Capital, and Earlybird Health, Sense is growing rapidly as it prepares to launch Veros COVID-19 and build a portfolio of additional tests for other diseases.

For more information, visit https://sense-bio.com/ and follow the company on Twitter at @sensedx1 and on LinkedIn at @Sense Biodetection Ltd.

About Una Health

Una Health is all about taking an innovative approach to diagnostics to revolutionise the patient pathway and improve the overall patient journey.

We specialise in pathology and point of care diagnostics; supplying specialist, innovative and appropriate healthcare solutions.

We offer exceptional levels of experience, expertise and support. However, our real skill is in combining leading technology with a different way of thinking, to provide rapid, reliable results that make more efficient use.

For more information, visit https://unahealth.co.uk/ and following the company on Twitter @unahealth and on LinkedIn at @Una_Health.

Contacts

Media:

Mike Sinclair

Halsin Partners

+44 7968 022075

[email protected]